Retour aux projets

17003.1 PFLS-LS

Development of stable affinity columns for antibody purification

Résumé

Development of stable affinity columns for antibody purification

Textes supplémentaires

Abstract

Monoclonal antibodies (MAbs) account for a large share of the rapidly growing biological drugs|market. Whilst the market for such drugs is expected to reach $62.3 billion in 2015, the biggest|obstacle in MAb production ¿ purification, is still suboptimal. Expensive Protein A resins are|used but they can be sensitive to elution and sterilization conditions. In combination with|ChromaCon¿s proprietary technology, this project aims to develop and commercialize a novel,|efficient and cost effective antibody purification process using a novel affinity reagent for|humanized antibodies.

Participants

Michael Bavand

Wirtschaftspartner

michael.bavand@chromacon.ch

ChromaCon AG Michael Bavand Technoparkstrasse 1 8005 Zürich ZH CH

Jeffrey Bode

Kontaktperson

bode@org.chem.ethz.ch

ETH Zürich Jeffrey Bode Wolfgang-Pauli-Strasse 10 8093 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2015-01-31
Date de fin
2017-10-31
Coûts totaux approuvés
CHF 368184.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%